Saturday 17 October 2026
Export NGNE’s income statement to Excel — free account
Neurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.
23.27
0.68
−2.84%
Follow NGNE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(42.25%) | (31.41%) | (37.25%) | (45.32%) | |
| (37.67%) | (28.94%) | (34.10%) | (41.02%) | ||
ROIC |
(44,393.25%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(31.61%) | (33.69%) | (41.03%) | (50.70%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.70) | (3.67) | (3.73) | (3.89) | |
Free Cash Flow |
(78.41) | (78.36) | (83.20) | (87.71) | |
Capital Expenditures |
(1.17) | (1.18) | (0.68) | (0.89) | |
| Other line items | |||||
Cash ROIC |
(14.77%) | (14.68%) | (17.30%) | (19.82%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(16,218.33) | (20,665.60) | — | — | |
Operating CF/Net income |
0.91 | 0.85 | 0.84 | 0.78 | |
Depreciation/Fixed assets |
(0.14) | (0.11) | 0.00 | 0.10 | |
Capex/Depreciation |
0.62 | 0.82 | (32.57) | (0.74) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.65) | (3.62) | (3.70) | (3.85) | |
Capex per Share |
(0.06) | (0.06) | (0.03) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates